阿斯利康疫苗前因子V Leiden突变检测

IF 0.2 Q4 PERIPHERAL VASCULAR DISEASE

Italian Journal of Vascular and Endovascular Surgery Pub Date : 2022-10-01 DOI:10.23736/s1824-4777.22.01533-9

A. Hosny, M. Sharkawy

{"title":"阿斯利康疫苗前因子V Leiden突变检测","authors":"A. Hosny, M. Sharkawy","doi":"10.23736/s1824-4777.22.01533-9","DOIUrl":null,"url":null,"abstract":"BacKgrouNd: on the beginning of 2020 the world woke up with a novel coronavirus disease (coVId-19) pandemic caused by sarscoV-2, started in Wuhan, china. several types of vaccine appeared, one of them was astraZeneca (astraZenca, cambridge, uK) vaccine. METHOD(S): This is a single-center retrospective study which included 9 patients who developed DVT after the first dose of AstraZeneca vaccine. they were screened for thrombophilia, including factor V leiden mutation. rEsults: they were found positive for factor V leiden mutation and were treated by Noacs. also, they were advised to delay second dose for 3 months and to shift to another vaccine like sinopharm (china National Pharmaceutical group, Beijing, china). coNclusIoNs: alert should be raised for patients with factor V leiden mutation having a second dose;and for the treatment of the thrombosis condition. Copyright © 2022 EdIZIoNI MINErVa MEdIca.","PeriodicalId":54914,"journal":{"name":"Italian Journal of Vascular and Endovascular Surgery","volume":"1 1","pages":""},"PeriodicalIF":0.2000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Factor V Leiden mutation detection before AstraZeneca vaccine\",\"authors\":\"A. Hosny, M. Sharkawy\",\"doi\":\"10.23736/s1824-4777.22.01533-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"BacKgrouNd: on the beginning of 2020 the world woke up with a novel coronavirus disease (coVId-19) pandemic caused by sarscoV-2, started in Wuhan, china. several types of vaccine appeared, one of them was astraZeneca (astraZenca, cambridge, uK) vaccine. METHOD(S): This is a single-center retrospective study which included 9 patients who developed DVT after the first dose of AstraZeneca vaccine. they were screened for thrombophilia, including factor V leiden mutation. rEsults: they were found positive for factor V leiden mutation and were treated by Noacs. also, they were advised to delay second dose for 3 months and to shift to another vaccine like sinopharm (china National Pharmaceutical group, Beijing, china). coNclusIoNs: alert should be raised for patients with factor V leiden mutation having a second dose;and for the treatment of the thrombosis condition. Copyright © 2022 EdIZIoNI MINErVa MEdIca.\",\"PeriodicalId\":54914,\"journal\":{\"name\":\"Italian Journal of Vascular and Endovascular Surgery\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2022-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Italian Journal of Vascular and Endovascular Surgery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.23736/s1824-4777.22.01533-9\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PERIPHERAL VASCULAR DISEASE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Italian Journal of Vascular and Endovascular Surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23736/s1824-4777.22.01533-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

摘要

背景:2020年初，由sarscoV-2引起的新型冠状病毒病(coVId-19)大流行在中国武汉开始。出现了几种疫苗，其中一种是阿斯利康(astraZeneca, cambridge, uK)疫苗。方法:这是一项单中心回顾性研究，纳入了9例首次接种阿斯利康疫苗后发生DVT的患者。他们被筛查是否有血栓，包括因子V leiden突变。结果:经Noacs治疗后，发现因子V leiden突变阳性。此外，建议他们将第二次接种推迟3个月，并改用另一种疫苗，如国药集团(中国医药集团公司，中国北京)。结论:对二次给药的因子V leiden突变患者应提高警惕，对血栓形成的治疗应提高警惕。版权所有©2022 EdIZIoNI MINErVa MEdIca。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Factor V Leiden mutation detection before AstraZeneca vaccine

BacKgrouNd: on the beginning of 2020 the world woke up with a novel coronavirus disease (coVId-19) pandemic caused by sarscoV-2, started in Wuhan, china. several types of vaccine appeared, one of them was astraZeneca (astraZenca, cambridge, uK) vaccine. METHOD(S): This is a single-center retrospective study which included 9 patients who developed DVT after the first dose of AstraZeneca vaccine. they were screened for thrombophilia, including factor V leiden mutation. rEsults: they were found positive for factor V leiden mutation and were treated by Noacs. also, they were advised to delay second dose for 3 months and to shift to another vaccine like sinopharm (china National Pharmaceutical group, Beijing, china). coNclusIoNs: alert should be raised for patients with factor V leiden mutation having a second dose;and for the treatment of the thrombosis condition. Copyright © 2022 EdIZIoNI MINErVa MEdIca.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Italian Journal of Vascular and Endovascular Surgery PERIPHERAL VASCULAR DISEASE-

CiteScore

1.00

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： The Italian Journal of Vascular and Endovascular Surgery publishes scientific papers on vascular surgery. Manuscripts may be submitted in the form of editorials, original articles, review articles, case reports, therapeutical notes, special articles and letters to the Editor.